The veterinary profession is dedicated to the prevention of animal suffering and disease, as well as the protection of the public health. As such, the AVMA believes that it is vitally important to maintain and encourage the development of new technologies to fulfill this commitment. Accordingly, the veterinary profession should not be denied access to flouroquinolones. The AVMA believes that the new animal drug application (NADA) process provides a well-established scientific basis for animal drug approvals. The AVMA believes that current concerns raised about the future approvals of flouroquinolones for use in animals ignore this process and the safeguards for the public health which are inherent in it. The AVMA believes the FDA must adhere to the established NADA approval procedures to maintain the scientific integrity of the process.